Literature DB >> 14610153

Chronic ataxic neuropathy with cold agglutinins: atypical phenotype and response to anti-CD20 antibodies.

K Siddiqui1, E Cahalane, M Keogan, O Hardiman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610153     DOI: 10.1212/wnl.61.9.1307

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

1.  Successful treatment with rituximab of one patient with CANOMAD neuropathy.

Authors:  Emilien Delmont; P Y Jeandel; A M Hubert; L Marcq; J Boucraut; C Desnuelle
Journal:  J Neurol       Date:  2009-12-04       Impact factor: 4.849

Review 2.  Molecularly targeted therapies for dysimmune neuropathies.

Authors:  Andreas A Argyriou
Journal:  Mol Med       Date:  2009-05-05       Impact factor: 6.354

3.  Successful treatment of CANOMAD with IVIg and rituximab.

Authors:  Wolfgang N Löscher; Alexander Woertz; Monika Wallnöfer; Julia V Wanschitz; Gerhard Luef
Journal:  J Neurol       Date:  2013-02-12       Impact factor: 4.849

Review 4.  Sustained response to subcutaneous immunoglobulins in chronic ataxic neuropathy with anti-disialosyl IgM antibodies (CANDA): report of two cases and review of the literature.

Authors:  D Marastoni; L Africa; G M Fabrizi; F Giannini; A Peretti; S Bocci; L Insana; S Ferrari; F Ginanneschi; G Zanette
Journal:  J Neurol       Date:  2020-04-28       Impact factor: 4.849

5.  CANOMAD responding to weekly treatment with intravenous immunoglobulin (IVIg).

Authors:  Martin Krenn; Geoff Keir; Udo Carl Wieshmann
Journal:  BMJ Case Rep       Date:  2014-04-10

6.  CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA).

Authors:  Rocio Garcia-Santibanez; Craig M Zaidman; R Brian Sommerville; Glenn Lopate; Conrad C Weihl; Alan Pestronk; Robert C Bucelli
Journal:  J Neurol       Date:  2018-04-09       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.